First-of-its-kind medication shows promise for liver disease patients
In this 5-minute check in, we review the promising phase 3 data from a randomized trial that led to FDA approval including the results, the implications for patient care, and the potential to transform the landscape of NASH management
Guest: Dr. Justin Reynolds, Associate Professor, Creighton University School of Medicine, Gastroenterologist and Transplant Hepatologist, St Joseph's Hospital and Medical Center Transplant Center in Phoenix, Arizona.
Study: https://www.nejm.org/doi/10.1056/NEJMoa2309000
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More